Teladoc Health, Inc. Expected to Earn Q3 2022 Earnings of ($0.49) Per Share (NYSE:TDOC)

Teladoc Health, Inc. (NYSE:TDOCGet Rating) – Equities researchers at KeyCorp issued their Q3 2022 earnings per share estimates for Teladoc Health in a report released on Thursday, September 15th. KeyCorp analyst S. Schoenhaus forecasts that the health services provider will post earnings of ($0.49) per share for the quarter. KeyCorp currently has a “Sector Weight” rating on the stock. The consensus estimate for Teladoc Health’s current full-year earnings is ($1.54) per share. KeyCorp also issued estimates for Teladoc Health’s FY2023 earnings at ($1.36) EPS.

Teladoc Health (NYSE:TDOCGet Rating) last posted its quarterly earnings results on Wednesday, July 27th. The health services provider reported ($0.44) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.71) by $0.27. Teladoc Health had a negative return on equity of 2.04% and a negative net margin of 441.94%. The company had revenue of $592.38 million for the quarter, compared to analysts’ expectations of $586.86 million.

A number of other research analysts have also commented on the stock. Guggenheim lowered shares of Teladoc Health from a “neutral” rating to a “sell” rating and set a $25.00 price objective for the company. in a research report on Wednesday, August 17th. Cowen cut shares of Teladoc Health from an “outperform” rating to a “market perform” rating and decreased their price target for the company from $58.00 to $34.00 in a research note on Tuesday, August 2nd. Oppenheimer decreased their price target on shares of Teladoc Health from $65.00 to $55.00 and set an “outperform” rating on the stock in a research note on Thursday, July 28th. The Goldman Sachs Group cut shares of Teladoc Health from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $55.00 to $36.00 in a research note on Thursday, July 28th. Finally, Cowen cut shares of Teladoc Health from an “outperform” rating to a “market perform” rating and reduced their price objective for the company from $58.00 to $34.00 in a research note on Tuesday, August 2nd. Two investment analysts have rated the stock with a sell rating, twenty-four have issued a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $66.88.

Teladoc Health Trading Down 1.2 %

Shares of NYSE:TDOC opened at $30.13 on Monday. The stock has a market capitalization of $4.86 billion, a PE ratio of -0.49 and a beta of 0.86. Teladoc Health has a 1 year low of $27.38 and a 1 year high of $156.82. The firm has a fifty day moving average price of $35.88 and a 200 day moving average price of $43.23. The company has a current ratio of 3.38, a quick ratio of 3.22 and a debt-to-equity ratio of 0.25.

Insider Activity

In other news, CFO Mala Murthy sold 4,053 shares of Teladoc Health stock in a transaction dated Monday, June 27th. The shares were sold at an average price of $37.32, for a total value of $151,257.96. Following the completion of the transaction, the chief financial officer now owns 27,295 shares of the company’s stock, valued at approximately $1,018,649.40. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, insider Arnnon Geshuri sold 4,098 shares of Teladoc Health stock in a transaction dated Friday, August 26th. The shares were sold at an average price of $34.27, for a total transaction of $140,438.46. Following the completion of the sale, the insider now owns 76,182 shares of the company’s stock, valued at approximately $2,610,757.14. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Mala Murthy sold 4,053 shares of Teladoc Health stock in a transaction dated Monday, June 27th. The stock was sold at an average price of $37.32, for a total transaction of $151,257.96. Following the sale, the chief financial officer now directly owns 27,295 shares of the company’s stock, valued at approximately $1,018,649.40. The disclosure for this sale can be found here. Insiders sold a total of 10,151 shares of company stock valued at $370,316 in the last quarter. Company insiders own 1.55% of the company’s stock.

Institutional Trading of Teladoc Health

Several hedge funds and other institutional investors have recently bought and sold shares of TDOC. Dimensional Fund Advisors LP raised its stake in Teladoc Health by 5.2% in the 4th quarter. Dimensional Fund Advisors LP now owns 388,293 shares of the health services provider’s stock worth $35,664,000 after purchasing an additional 19,109 shares in the last quarter. Rhumbline Advisers raised its position in shares of Teladoc Health by 2.9% in the 4th quarter. Rhumbline Advisers now owns 127,995 shares of the health services provider’s stock valued at $11,753,000 after buying an additional 3,565 shares in the last quarter. abrdn plc raised its position in shares of Teladoc Health by 1.1% in the 4th quarter. abrdn plc now owns 21,722 shares of the health services provider’s stock valued at $1,995,000 after buying an additional 242 shares in the last quarter. Charles Schwab Investment Management Inc. raised its position in shares of Teladoc Health by 2.3% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 481,716 shares of the health services provider’s stock valued at $44,232,000 after buying an additional 10,673 shares in the last quarter. Finally, Geode Capital Management LLC raised its position in shares of Teladoc Health by 4.7% in the 4th quarter. Geode Capital Management LLC now owns 1,917,908 shares of the health services provider’s stock valued at $175,868,000 after buying an additional 85,362 shares in the last quarter. Institutional investors and hedge funds own 92.46% of the company’s stock.

Teladoc Health Company Profile

(Get Rating)

Teladoc Health, Inc provides virtual healthcare services in the United States and internationally. The company offers a portfolio of services and solutions covering non-urgent, episodic, chronic, and complicated medical conditions, including diabetes, hypertension, chronic kidney disease, cancer, congestive heart failure, and mental health conditions.

Recommended Stories

Earnings History and Estimates for Teladoc Health (NYSE:TDOC)

Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.